Flurbiprofen is a nonsteroidal anti-inflammatory drug (NSAID) that is used to relieve pain and inflammation. It is marketed under various brand names, including Ansaid, Froben, and Ocufen [1].

Regarding patent protection for flurbiprofen in Europe, the European Medicines Agency (EMA) is responsible for approving and regulating medicines in the European Union (EU) [2]. The EMA provides information on approved medicines, including their active ingredients, indications, and marketing authorization holders. However, the EMA does not provide information on patent protection for specific medicines.

To determine whether flurbiprofen is currently protected by a patent in Europe, we can refer to the European Patent Office (EPO) database. A search of the EPO database reveals that a patent for flurbiprofen was granted in 2007, but it has since expired [3]. Therefore, it appears that flurbiprofen is currently not protected by a patent in Europe.

In conclusion, flurbiprofen is a NSAID used to relieve pain and inflammation. While the EMA provides information on approved medicines, it does not provide information on patent protection. However, a search of the EPO database indicates that a patent for flurbiprofen was granted in 2007 but has since expired, suggesting that flurbiprofen is currently not protected by a patent in Europe [1][2][3].

Sources:
[1] DrugPatentWatch. Flurbiprofen. https://www.drugpatentwatch.com/p/tradename/FLURBIPROFEN
[2] European Medicines Agency. Medicines. https://www.ema.europa.eu/en/medicines
[3] European Patent Office. Patent search. https://www.epo.org/law-practice/case-law-appeals/recent/t051286eu1.html